top of page

Changing the paradigm for colorectal cancer: Clinical practice & drug development

ENDPOINTS STUDIO
9/20/22, 5:00 PM
America/New York GMT -4 summer

Description

Many ongoing studies aim to improve treatment and outcomes for early-stage colorectal cancer, including guiding adjuvant chemotherapy decisions and bringing targeted therapies and immunotherapies into the early-stage setting.

 

Join us for a webinar and panel discussion on the ways in which the paradigm for colorectal cancer care is changing, particularly in the context of the latest 2022 data from ESMO, ASCO, and ASCO GI.

 

We will hear from Dr. Scott Kopetz, Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology at MD Anderson and the principal investigator of several Phase 1, 2, and 3 clinical trials, including trials for patients with BRAF mutated colorectal cancer that led to new standards of care. He will be joined by Dr. Angel Rodriguez, Oncology Medical Director at Natera and previously Director of the Clinical Trial Office at Houston Methodist Cancer Center.

 

OUR SPEAKERS WILL DISCUSS:

  • Unmet needs in the management of patients with colorectal cancer
  • Trends in colorectal cancer screening, clinical management, and drug development
  • How ctDNA can be used in clinical practice to assess need for adjuvant chemotherapy
  • The role of ctDNA in accelerating drug development for early-stage disease
Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Arsalan Arif

Unmet needs in the management of patients with colorectal cancer, Trends in colorectal cancer screening, clinical management, and drug development, How ctDNA can be used in clinical practice to assess need for adjuvant chemotherapy, The role of ctDNA in accelerating drug development for early-stage disease

Inglês

Description

Speakers

Scott Kopetz, Angel Rodriguez, John Simmons

Speakers
Link to Event
Banner
Registro
bottom of page